Despite considerable advances in PTE diagnosis, still there are existing dilemmas in daily practice for physicians. Although PTE is known as a lethal disease, several studies reveal that the increase in CTPA has not resulted in an improvement in patient outcome (
2,
3). During a 72-month follow-up of 93 patients with acute PTE isolated to subsegmental arteries without other evidence of deep venous thrombosis, no mortality was reported even in 22 patients who were observed with no therapy (
2). Anderson et al. reported PTE overdiagnosis in a study that they randomized 1417 patients with likely clinical probability to receive CTPA or ventilation-perfusion (VQ) scanning as diagnostic imaging modality. Although CTPA detected more PTE than VQ scanning (19.2% versus 14.2%, P = 0.01), there was no significant difference in mortality over a three-month follow up (
4). In New York State, during the period when CTPA became the dominant imaging technique for suspected PTE, PTE diagnosis nearly doubled between 1994 and 2004, but the mortality remained unchanged (
3). These findings suggest that despite over diagnosis of PTE (diagnosis of clinically insignificant disease) with CT pulmonary angiography, clinically significant disease did not change. In spite of these results and emphasizing on adherence to the existing guideline, there is still excessive unjustified fear of this disease leading to unnecessary extensive work-up including CTPA. In approaching a patient with suspected PTE, PIOPED II study (Prospective Investigation of Pulmonary Embolism Diagnosis II) recommended assessing clinical probability (measuring Wells score) before the diagnostic imaging plan (
5). Therefore, CTPA is not recommended when clinical pretest probability is unlikely and a sensitive D-dimer test result is negative. When clinical pretest probability is likely or a sensitive D-dimer test result is positive in a patient with an unlikely clinical risk, this study recommends performing imaging study. Non adherence to these recommendations and ordering excessive CTPA in a clinical setting exposes the patients to several risks of which overdiagnosis and/or overtreatment is the most serious (
5). VQ scanning was introduced in the mid-1960s as the first diagnostic imaging modality for pulmonary embolism (
6). Nevertheless, its main disadvantage was inconclusive results. Multi-detector CTPA was introduced in 1998 with higher imaging resolution and more definitive results. Regarding the availability of this modality, there was an explosion in CTPA ordering for patients with suspected PTE. Weiss et al. found CTPA as the first line test ordered by emergency department physicians for approaching PTE (
7). According to health maintenance organization reports, performing CTPA was increased to 14-fold (from 0.3 to 4.0 per 1000), while use of VQ scan decreased by 52% (from 2.3 to 1.1 per 1000) from 2001 to 2008 (
8). Multi-detector CTPA is now the diagnostic imaging of choice for evaluation of suspected PTE. Sensitivity, specificity, positive predictive value, and negative predictive value was 83%, 96%, 86%, and 95%, respectively in the PIOPED II study which used multi-detector CTPA (4-, 8-, and 16-row) as the diagnostic imaging modality (
5). Adams et al. (
9) measured loyalty to the PIOPED II recommendations in patients with suspected PTE. They found that the overall rate of pulmonary embolism was 9.7% and more than half of the 3500 (54.5%) CTPAs were performed to investigate PTE in patients who did not have a sufficiently high clinical risk or had a negative D-dimer value. In our study, which was performed in an educational center, 50.6% of the CTPAs were requested for those with a low clinical probability (score ≤ 4). This result highlights the overuse of this costly and potentially harmful mean of diagnosis. On the other hand, three patients in the likely clinical risk group were inappropriately checked for D-dimer. Although the results were negative, CTPA showed PTE in two of them emphasizing that a negative D-dimer result cannot rule out PTE in patients with a likely clinical risk. PTE prevalence among patients included in the multicenter PIOPED II study was 23%, but a study conducted by Costantino et al. suggests that there should be at least a 10% prevalence rate of PTE among those patients undergoing CTPA (
10). Overuse of CTPA in diagnosing PTE is not cost-benefit, exposing the patients to false-positive test results, contrast induced nephropathy, and carcinogenic radiation exposure. It is possible to avoid unnecessary imaging requests by more adherence to PIOPED II investigators recommendation (
11). This could be achieved with wiser and more accurate clinical risk assessment by more experienced clinicians in the thromboembolic field, especially in the setting of educational hospitals in which the decisions of less trained physicians are influenced by unwarranted fears of disease outcome. To the best of our knowledge, this is the first report that studied the appropriate use of CTPA in an educational hospital. For more comprehensive findings, we recommend larger prospective controlled studies in such hospitals.